Brainstorm Secures Additional $1 Million Financing
Written by Emily J. Thompson, Senior Investment Analyst
Updated: 6 days ago
0mins
Source: PRnewswire
- Financing Progress: Brainstorm Cell Therapeutics has completed a second strategic private placement of $1 million in February 2026, bringing the total capital raised this month to $2 million, which is expected to provide a stable valuation foundation and support its clinical objectives.
- Increased Market Confidence: CEO Chaim Lebovits stated that securing a cumulative $2 million in a single week reflects growing market confidence in the company's trajectory, particularly as the stock approaches the $1.00 warrant target.
- Clinical Trial Preparation: The proceeds from this financing will be used for working capital and general corporate purposes, especially to support the preparatory work for the upcoming Phase 3 clinical trial for ALS, thereby extending the company's operational runway.
- Platform Technology Advantage: Brainstorm's NurOwn® technology platform focuses on treating neurodegenerative diseases and has received Orphan Drug designation from both the FDA and EMA, highlighting its potential competitiveness and market opportunities within the industry.
About the author
Emily J. Thompson
Emily J. Thompson, a Chartered Financial Analyst (CFA) with 12 years in investment research, graduated with honors from the Wharton School. Specializing in industrial and technology stocks, she provides in-depth analysis for Intellectia’s earnings and market brief reports.
